Actively Recruiting
Mechanistic Insights From Bronchoscopy Airway Samples
Led by University of California, San Francisco · Updated on 2026-04-24
24
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
N
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to examine the mechanisms of asthma. The investigators are comparing the cells of individuals with and without asthma and looking at the roles various parts of the cell play in the production and secretion of mucus.
CONDITIONS
Official Title
Mechanistic Insights From Bronchoscopy Airway Samples
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female subjects between the ages of 18 and 70 years
- Ability to provide written informed consent and comply with study requirements
- For healthy controls: no hyperreactivity to methacholine (PC20 FEV1 Methacholine >16 mg/mL) and no history of allergic rhinitis or seasonal allergies
- For asthmatics: history of asthma
- No use of oral or inhaled corticosteroids for asthma treatment during the past 6 weeks
- For asthmatics: hyperreactivity to methacholine (PC20 FEV1 Methacholine < 8 mg/mL)
You will not qualify if you...
- Current smokers, defined as smoking more than 5 cigarettes in the past 12 months or having smoked within the last 8 weeks, or former smokers with a total smoking history of 10 pack-years or more
- Pregnant, breastfeeding, or unwilling to practice birth control during the study
- History of lung disease other than asthma
- History of prior esophageal hernia surgery
- Medical diseases that may increase risk from study procedures or affect study results as judged by the investigator
- Current participation in another investigational drug trial
- Use of prohibited medications such as Astemizole (within 12 weeks), steroids (oral, inhaled, nasal within 6 weeks), Nedocromil sodium or sodium cromoglycate (within 4 weeks), long-acting methylxantines (within 2 days), short-acting methylxantines (within 12 hours), Montelukast or Zafirlukast (within 7 days), Salmeterol (within 2 days), or Omalizumab (within 6 months)
- Withholding of aspirin or NSAIDs for 2 days prior to bronchoscopy
- Withholding of short-acting bronchodilators for 6 hours, short-acting anticholinergics for 8 hours, and antihistamines for 3 days before each clinic visit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
C
Christine P Nguyen, BS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here